发明名称 Long-Acting Blood Sugar Decreasing Fusion Protein
摘要 The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.
申请公布号 US2016222079(A1) 申请公布日期 2016.08.04
申请号 US201414898698 申请日期 2014.07.02
申请人 Genor Biopharma Co., Ltd. 发明人 ZHOU Joe;ZHOU Qing;CHEN Rulei;SHI Shu;NIAN Weihong;YAN Hongbin
分类号 C07K14/605 主分类号 C07K14/605
代理机构 代理人
主权项
地址 Shanghai CN